News

  1. Aegis Sciences Corporation Announces Its Adoption of Self-Regulatory Standards for NPS Testing

    NASHVILLE, TN. (February 5, 2024) – Nearly 107,000 Americans died from a drug overdose in 2021, according to the Centers for Disease Control and Prevention.…

    NASHVILLE, TN. (February 5, 2024) – Nearly 107,000 Americans died from a drug overdose in 2021, according to the Centers for Disease Control and Prevention. More than 80,000 of those deaths (75 percent) were opioid-related and, of those, nearly 71,000 (88 percent) involved high-potency synthetic opioids.1 Synthetic opioids are driving the opioid overdose epidemic: the number of synthetic opioid-related…

  2. Aegis Sciences Corporation Achieves HITRUST Risk-based, 2-year Certification Demonstrating the Highest Level of Information Protection Assurance

    HITRUST Risk-based, 2-year (r2) Certification validates Aegis Sciences Corporation continues its commitment to strong cybersecurity and meeting key regulations…

    HITRUST Risk-based, 2-year (r2) Certification validates Aegis Sciences Corporation continues its commitment to strong cybersecurity and meeting key regulations to protect sensitive data.

  3. Aegis Sciences Announces Expanded Testing for Marijuana

    NASHVILLE, TN. (December 5, 2023) – Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce it will be updating…

    NASHVILLE, TN. (December 5, 2023) – Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce it will be updating their urine testing for marijuana and other cannabinoids to include Delta-8 Carboxy-THC and Cannabidiol, in addition to Delta-9 Carboxy-THC. Delta-8 and delta-9 THC are psychoactive cannabinoids that are subject to variable state and federal regulations.…

  4. Aegis Sciences Corporation Further Expands Testing for Novel Psychoactive Substances

    NASHVILLE, TN. (September 12, 2023) – Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce another expansion…

    NASHVILLE, TN. (September 12, 2023) – Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce another expansion of novel psychoactive substance (NPS) testing for its clients. The NPS test menu includes expanded offerings for designer opioids, designer benzodiazepines, synthetic cannabinoids, synthetic stimulants, hallucinogens/dissociatives, and other substances…

  5. Aegis receives Distinguished Abstract recognition

    The study, Evidence of Missed Novel Psychoactive Substances (NPS) in Unexpected Fentanyl Positives, by Aegis Sciences Corporation was recognized by the…

    The study, Evidence of Missed Novel Psychoactive Substances (NPS) in Unexpected Fentanyl Positives, by Aegis Sciences Corporation was recognized by the AACC Annual Scientific Meeting & Clinical Lab Expo.Each year, a group of Academy fellows reviews the abstracts submitted to the AACC Annual Scientific Meeting & Clinical Lab Expo and selects several for distinction. The study evaluated how common novel…

  6. The Results of our Client Satisfaction Survey 2023

    Aegis Sciences Corporation has achieved great success with its sales and service according to our latest Client Satisfaction Survey.  Our toxicology services…

    Aegis Sciences Corporation has achieved great success with its sales and service according to our latest Client Satisfaction Survey.  Our toxicology services provide insights to help clinicians identify medication compliance, explore causes of non-adherence, and reduce risk for adverse events and overdose. Providers agree that our services make a difference for their practice and for their patients. “I…

  7. Aegis Selected as a UnitedHealthcare Preferred Lab Network Provider for the Second Year in a Row

    NASHVILLE, Tenn., July 1, 2023 – Aegis is pleased to announce that following a rigorous review process, it will continue to participate as a UnitedHealthcare…

    NASHVILLE, Tenn., July 1, 2023 – Aegis is pleased to announce that following a rigorous review process, it will continue to participate as a UnitedHealthcare Preferred Lab Network (PLN) provider for 2023-2024. The Preferred Lab Network consists of currently contracted independent, freestanding laboratory care providers that have met higher standards for access, cost, data, quality, and service. For…

  8. The Tip of the Iceberg

    The Tip of the Iceberg

    Aegis recent panelist, Ryan S. Alexander, DO, MPH, has released an op-ed where he expresses the need for testing in an uncertain drug landscape.

    Aegis recent panelist, Ryan S. Alexander, DO, MPH, has released an op-ed where he expresses the need for testing in an uncertain drug landscape.

  9. Xylazine Use Shows Need For Testing

    Xylazine Use Shows Need For Testing

    Aegis provider and recent panelist, Leigh Brooks, APRN, FNP-C, has released an op-ed where she shares her firsthand experience with dangerous drugs like…

    Aegis provider and recent panelist, Leigh Brooks, APRN, FNP-C, has released an op-ed where she shares her firsthand experience with dangerous drugs like xylazine and how comprehensive testing and education can make an impact.

  10. Testing is Crucial in the Fight Against Xylazine

    Testing is Crucial in the Fight Against Xylazine

    Aegis Clinical Pharmacist, Andrew Holt, Pharm.D., BCMAS, CPGx, has released an op-ed where he expresses the importance of clinical definitive testing for…

    Aegis Clinical Pharmacist, Andrew Holt, Pharm.D., BCMAS, CPGx, has released an op-ed where he expresses the importance of clinical definitive testing for fentanyl-xylazine mixtures, an emerging threat to the United States.